Skip to Content

Major Neurological Disorders on the Rise in the United States

WEDNESDAY, Nov. 4, 2020 -- The burden of neurological disorders in the United States increased almost universally from 1990 to 2017, according to a study published online Nov. 2 in JAMA Neurology.

Valery L. Feigin, M.D., Ph.D., from the Auckland University of Technology in New Zealand, and colleagues used data from the Global Burden of Disease 2017 study to estimate the burden of major neurological disorders in the United States by age and sex from 1990 to 2017.

The researchers found that the three most burdensome neurological disorders in the United States by absolute number of disability-adjusted life-years (DALYs) were stroke (3.58 million DALYs), Alzheimer disease and other dementias (2.55 million DALYs), and migraine (2.40 million DALYs). During the study period, the burden of almost all neurological disorders (absolute number of incident, prevalent, and fatal cases, as well as DALYs) increased, largely due to the aging of the population. Traumatic brain injury incidence (−29.1 percent); spinal cord injury prevalence (−38.5 percent); meningitis prevalence (−44.8 percent), deaths (−64.4 percent), and DALYs (−66.9 percent); and encephalitis DALYs (−25.8 percent) were the exceptions.

"The information reported in this article can be used by health care professionals and policy makers at the national and state levels to advance their health care planning and resource allocation to prevent and reduce the burden of neurological disorders," the authors write.

Several authors disclosed financial ties to the biotechnology and pharmaceutical industries.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: November 2020

Read this next

Memory Preserved in Rare Aphasia Tied to Alzheimer Disease

FRIDAY, Jan. 15, 2021 -- Individuals with primary progressive aphasia (PPA) associated with Alzheimer disease (AD) have longitudinally preserved episodic memory, according to a...

Greater Levels of Exercise May Protect Brain in Later Life

THURSDAY, Jan. 14, 2021 -- Greater levels of moderate- to vigorous-intensity physical activity (MVPA) in midlife may protect against cerebrovascular sequelae in later life,...

Experimental Drug for Alzheimer Disease Shows Promise

TUESDAY, Jan. 12, 2021 -- Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab. The two-year,...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.